References with PepMix™ Peptide Pools - Tumor Associated Antigens

JPT's Tumor Associated Antigens for Research

PepMix™ Peptide Pools are instrumental in cancer immunotherapy, particularly for exploring tumor-associated antigens and improving T cell responses. JPT’s PepMix™ Peptide Pools support the development of novel cancer vaccines and therapeutic strategies targeting tumor-specific markers. Below, you will find key studies referencing JPT’s PepMix™ Peptide Pools in research.

References with PepMix™ Peptide Pools - Tumor Associated Antigens

2026

Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancerLecoester et al., Oncoimmunology (2026) - PMID: 41749511Product used: PepMix™ Human (NY-ESO-1), PepMix™ Human (TERT)

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccinesMa et al., NPJ Vaccines (2026)Products used: PepMix™ VEEV (Spike Glycoprotein E2), PepMix™ Human (CEA), OVA (257-264) Chicken Ovalbumin Peptide - SIINFEKL, PepMix™ HIV-1 (GAG) Ultra

Peripheral rotavirus-specific T-cell responses following monovalent oral rotavirus vaccine in infantsNicols et al., NPJ Vaccines (2026)Product used: PepMix™ Human MOG (1-125) Peptide Pool

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trialMusher et al., Nature Medicine (2026)Product used: PepMix™ Human (Prame/OIP4), PepMix™ Human (SSX2), PepMix™ Human (Survivin), PepMix™ Human (MAGEA4), PepMix™ Human (NY-ESO-1)

High Concentrations of β2‐Microglobulin Do Not Inhibit In Vitro Generation of Functional Dendritic CellsTaborska et al., Journal of Immunological Research (2026) - PMID: 41503517Product used: PepMix™ Human (Prostate-specific antigen PSA)

Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphomaToner et al., Blood Advances (2026) - PMID: 40990939Products used: PepMix™ Human (MAGEA4), PepMix™ Human (Survivin), PepMix™ Human (Prame/OIP4)

2025

Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5Gan et al., Journal of Translational Medicine (2025) Products used: PepMix™ Human (FJX1), PepMix™ Human (MAGED4)

CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunityHwang et al., Science Immunology (2025) - PMID: 41417923Products used: PepMix™ Human (ErbB2_ECD), PepMix™ Human (ErbB2_ICD), PepMix™ HIV-1 (GAG) Ultra, Custom pepMix LacZ

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunityLaheurte et al., Cell Reports Medicine (2025) - PMID: 40543509Products used: PepMix™ Human (NY-ESO-1), PepMix™ HIV-1 (ENV) Ultra

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialLopez et al., Nature Medicine (2025) - PMID: 39762422Product used: Custom PepMix™ Peptide Pools

Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasisPinho et al., Cell Reports Medicine (2025) - PMID: 40730190Products used: PepMix™ Human (ErbB2_ECD), PepMix™ Human (ErbB2_ICD), PepMix™ Human (ACTL8), PepMix™ Human (PLAC1), PepMix™ Human (Prame/OIP4)

Loss of SMARCA4 leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic TypeRaupach et al., AACR Journals (2025) - PMID: 40407709Products used: SpotMix & CEFX Ultra SuperStim Pool

Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical StudiesSun et al., Advanced Science (2025) - PMID: 41134065Products used: PepMix™ Human (PD-L1) & other PepMix™ TAAs

Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trialThibaudin et al., Signal Transduction and Targeted Therapy (2025) - PMID: 39820336Product used: PepMix™ Human (NY-ESO-1)

Archive

Molecular mimicry in multisystem inflammatory syndrome in childrenBodansky et al., Nature (2024) - PMID: 39112696Product used: custom PepMix (SXN8)

Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigenspecific autoimmune diseasesSaggau et al., Immunity (2024) - PMID: 39226901Product used: PepMix™ Human (MOG)

Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccinecandidate (LecA+GLA-3M-052 liposomes) in rhesus macaquesAbhyankar et al., Human Vaccines & Immunotherapeutics (2024) - PMID 39090779Product used: custom PepMix

Vaccination with Tozimameran Induces T-Cell Activation, but Not Senescent or Exhaustive Alterations, in Kidney Transplant RecipientsStai et al,. Vaccines (2024) Product used: custom PepMix

Circulating tumor-associated antigen-specific IFN? + 4-1BB + CD8 + T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancerMurakami et al., Frontiers in Immunology (2024) Products used: PepMix Human (CEA), Human (TERT), Human (WT1/WT33), Human (Mucin-1)

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesKelly et al., Nature Medicine (2024)

Multimodal single-cell profiling of T lymphocytes in infection and cancerBieberich, Dissertation (2024)Products used: PepMix Human (CEA), Human (MAGEA3), Human (NY-ESO-2), Human (WT1/WT33)

Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancerDailey et al., Human Vaccines & Immunotherapeutics (2024) - PMID: 38330990Products used: Custom PepMix (ESR1), PepMix HIV-1 (GAG) Ultra

Prophylactic Vaccination and Intratumoral Boost with HER2-Expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response against HER2-Positive Tumor CellsDelwar et al., Vaccines (2023) Product used: PepMix Human (ErbB2_ECD)

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsHall et al., Journal for Immunotherapy of Cancer (2023) - PMID: 37802604Product used: Custom PepMix

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancerRojas et al., Nature (2023) - PMID: 37165196Product used: Custom PepMix

Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation

Study of genes involved in HER2-positive breast cancer progression for identification of new therapeutic targetsRuzzi, Dissertation (2023)Product used: custom PepMix (HER2)

Untersuchungen zur Kreuzreaktivität von Cytomegalievirusspezifischen T-Lymphozyten und Tumorassoziierten Antigenen Weiß, Dissertation (2023)Products used: PepMix™ CMVA (pp65), Human (Mucin-1), Human (NY-ESO-1), Human (Prame/OIP4) & Human (WT1/WT33)

Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical DonorNemeckova et al., Current Oncology (2023) - PMID: 35621629Products used: PepMix Human (Prame/OIP4), Human (Mucin-1)

Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapyBonaventura et al., Immunology (2022)

Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer ImmunotherapyLewicky et al., Pharmaceutics (2022) Products used: PepMix Human (Mucin-1),Human (TERT), Human (CEA)

Interdependence of sequential CTL and NK cellcytotoxicityagainst melanomacellsFriedmann et al., Journal of Physiology (2022) Product used: PepMix Human (Melan-A/MART-1)

Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle VaccineRuzzi et al., Biomedicines (2022)

A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinomaTan et al., Nature Communications (2022) Product used: PepMix Human (Mucin-1)

CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer Lee et al., Science Immunology (2022) - PMID: 36026440Product used: PepMix Human (NY-ESO-1)

Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Tregreduction and effector T cell activationvan Pul et al., Science Immunology Products used: PepMix Human NY-ESO-1, Human Melan-A/MART1, CEFT Pool

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer Hoyos et al., Therapeutic Advances in Medical Oncology (2022)Products used: PepMix Human Survivin, Human NY-ESO-1, Human PRAME/OIP4, Human MAGEA4, Human SSX2

An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold TumorsFucikova et al., Clinical Cancer Research (2022) - PMID: 35536547Products used: PepMix Human (MAGAE3), Human ( MUC1)

Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical DonorNemeckova et al., Current Oncology (2022)

Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer Matsuzaki et al., Oncoimmunology (2022) - PMID: 35003898 Products used: PepMix™ Human (Claudin-6)

The human CXCR3 chemokine system in early differentiated CD8+ T cell function and solid tumorsTino Vollmer, Dissertation (2022)

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens Adam S Kibel et al., J Natl Cancer Inst. (2021) - PMID: 33630063 Products used: PM-PSA

Phenotype, Specificity and Avidity of Antitumour CD8+ T Cells in Melanoma Giacomo Oliveira et al., Nature, (2021)

Targeting Human Acyl-CoA:Cholesterol Acyltransferase as a Dual Viral and T Cell Metabolic Checkpoint Nathalie M. Schmidt et al., Nature Communications, (2021) Products used: PM-NYE, PM-MAGEA1, PM-AFP

Design of Peptides With High Affinity Binding to a Monoclonal Antibody as a Basis For Immunotherapy Surendra S. Negi et al., Peptides, (2021)

Early disappearance of tumor antigenreactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under antiPD-1 therapy Jonas Bochem et al., Journal Immunology, (2021) Products used: PM-MelA, PM-NYE

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization Anna Przybyla et al., Cancers (Basel) (2021) - PMID: 33435427 Products used: PM-GP100, PM-NYE, PM-Tyr, PM-MAGEA3, PM-MelA

Identification of Novel HLA-Restricted Preferentially Expressed Antigen in Melanoma Peptides to Facilitate Off-The-Shelf Tumor-Associated Antigen-Specific T-Cell Therapies Maja Stanojevic et al., Cytotherapy, (2021) Products used: PM-OIP4, PM-ACTS

Activation of Resident Memory T Cells For Cancer Immunotherapy David B. Masopust Jr. et.al., United States Patent Application 20210000935 (2021) - PMID: n.a.

Clinical Effects of Administering Leukemia-Specific Donor T Cells to Patients With AML/MDS Post-Allogeneic Transplant Premal Lulla et al., Blood (2020) - PMID: 33270816 Products used: PM-Survivin, PM-WT1, PM-OIP4, PM-NYE

Oncolytic Measles Virus Therapy Enhances Tumor Antigen-Specific T-Cell Responses in Patients With Multiple Myeloma Nandakumar Packiriswamy et al., Leukemia (2020) - PMID: 32327728 Products used: PM-MAGEA1, PM-MAGEA3, PM-MAGEC1, PM-WT1, PM-OIP4, PM-SSX2, PM-TERT, PM-p53, PM-MUC-1, PM-NYE

Pre-Transplant Assessment of pp65-Specific CD4 T Cell Responses Identifies CMV-Seropositive Patients Treated With rATG at Risk of Late Onset Infection Maria O. López-Oliva et al., Clinical Immunology (2020) - PMID: 31891764Products used: PM-IE1, PM-PP65-1

Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in MiceCarly M. Bliss et al., Molecular Therapy: Methods & Clinical Development (2019) - PMID: 31934599

Evaluation of Newcastle Disease Virus Mediated Dendritic Cell Activation and Cross‐Priming Tumor‐Specific Immune Responses Ex VivoQi Xu et al., International Journal of Cancer (2019) - PMID: 31584185

Natural T Cell Autoreactivity to Melanoma Antigens: Clonally Expanded Melanoma-Antigen Specific CD8 + Memory T Cells Can be Detected in Healthy HumansAnna Przybyla et al., Cancer Immunology, Immunotherapy (2019) - PMID: 30783693

The Human CD4 T Cell Response Against Mumps Virus Targets a Broadly Recognized Nucleoprotein EpitopeJelle de Wit et al., Journal of Virology (2019) - PMID: 30626672

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: a Mouse to Human Translational StudyErika J Crosby et al., Clinical Cancer Research (2019) - PMID: 30635338

Tel-eVax: a Genetic Vaccine Targeting Telomerase for Treatment of Canine LymphomaJoseph A. Impellizeri et al., Journal of Translational Medicine (2018) - PMID: 30537967

Over-Expression of PD-1 Does Not Predict Leukemic Relapse After Allogeneic Stem Cell TransplantationJain et al., Biology of Blood and Marrow Transplantation (2018) - PMID: n.a.

A Novel Allogeneic Off-The-Shelf Dendritic Cell Vaccine for Post-Remission Treatment of Elderly Patients with Acute Myeloid LeukemiaLoosdrecht et al., Cancer Immunol Immunother. (2018) - PMID: 30039426

PRAME Peptide‐Specific CD8+ T Cells Represent the Predominant Response Against Leukemia‐Associated Antigens (LAAs) in Healthy IndividualsMatko et al., European Journal of Immunology (2018) - PMID: 29738081

Combined IFN-γ and TNF-α Release Assay for Differentiating Active Tuberculosis from Latent Tuberculosis InfectionKim et al., Journal of Infection (2018) - PMID: 29746954

Personalized ex vivo Multiple Peptide Enrichment and Detection of T Cells Reactive to Multiple Tumor-associated Antigens in Prostate Cancer PatientsTaborska et al., Med Oncol. (2017) - PMID: 28866803

An Immunogenic Personal Neoantigen Vaccine for Patients with MelanomaOtt et al., Nature (2017) - PMID: 28678778

Personalized RNA Mutanome Vaccines Mobilize Poly-specific Therapeutic Immunity Against CancerSahin et al., Nature (2017) - PMID: 28678784

Spontaneous CD4+ and CD8+ T Cell Responses Directed Against Cancer Testis Antigens are Present in the Peripheral Blood of Testicular Cancer PatientsPearce et al., European Journal of Immunology (2017) - PMID: 28555838

Generation of T Cell Effectors Using Tumor Cell-Loaded Dendritic Cells for Adoptive T Cell TherapyVavrova et al., Medical Oncology (2016) - PMID: 27812850

A Phase I Study of Recombinant (r) Vaccinia-CEA (6D)-TRICOM and rFowlpox-CEA (6D)-TRICOM Vaccines with GM-CSF and IFN-α-2b in Patients with CEA-Expressing CarcinomasDuggan et al., Cancer Immunology, Immunotherapy (2016) - PMID: 27581603

Prognostic Impact of High Levels of Circulating Plasmacytoid Dendritic Cells in Breast CancerBailur et al., Journal of Translational Medicine (2016) - PMID: 27234566

Dysfunction of PSA-Specific CD8+ T Cells in Prostate Cancer Patients Correlates with CD38 and Tim-3 ExpressionJapp et al., Cancer Immunol Immunother. (2015) - PMID: 26289091

An HPV-E6/E7 Immunotherapy Plus PD-1 Checkpoint Inhibition Results in Tumor Regression and Reduction in PD-L1 ExpressionRice et al., Cancer Gene Therapy (2015) - PMID: 26337747

Survivin-Specific CD4+ T Cells are Decreased in Patients with Survivin-Positive MyelomaLocke et al., J Immunother Cancer (2015) - PMID: 25992291

A Phase I Trial Combining Decitabine/dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children with Relapsed or Therapy-Refractory Neuroblastoma and SarcomaKrishnadas et al., Cancer Immunol Immunother. (2015) - PMID: 26105625

Guidelines For the Automated Evaluation of Elispot AssaysJanetzki et al., Nature Protocols (2015) - PMID: 26110715

Functional Immunological Parameters Associated with Long-term Survival of Patients with Metastatic MelanomaHenning Zelba, Dissertation der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen (2015) - PMID: n.a

Presence of Circulating Her-2-reactive CD8 + T-Cells is Associated with Lower Frequencies of Myeloid-derived Suppressor Cells and Regulatory T Cells, and Better Survival in Elderly Breast Cancer PatientsKini Bailur et al., Breast Cancer Research (2015) - PMID: n.a.

STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic CellsOkada et al., Immunol Cell Biol. (2015) - PMID: 25582338

Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T CellsWeide et al., Clin Cancer Res. (2014) - PMID: 24323899

Vaccines Against Antigens Involved in Therapy Resistance and Methods of Using SameLyerly et al., US Patent 20,140,377,261 (2014) - PMID: n.a.

Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine TrialsSambor et al., J Immunol Methods. (2014) - PMID: 24787274

A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr virus (EBV) Target Antigens: a Phase I Trial in UK Patients with EBV-positive CancerTaylor et al., Clinical Cancer Research (2014) - PMID: 25124688

Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV MelanomaZelba et al., Clin. Cancer Res. (2014) - PMID: 24938524

Common Ewing Sarcoma-Associated Antigens Fail to Induce Natural T Cell Responses in Both Patients and Healthy IndividualsAltvater et al., Cancer Immunol Immunother. (2014) - PMID: 24973179

Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic ResponsesWeide et al., Cancer Immunology. (2014) - PMID: 24906352

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumor Lysate or Homogenate Combined with Immunomodulating Radiotherapy and/or Preleukapheresis IFN-α in Patients with Metastatic Melanoma: a Randomised “Proof-of principle” Phase II Studyde Rosa et al., J Transl Med. (2014) - PMID: 25053129

Normalizing ELISPOT Responses to T-cell Counts: a Novel Approach for Quantification of HCMV-Specific CD4+ and CD8+ T-Cell Responses in Kidney Transplant RecipientsCalarota et al., Journal of Clinical Virology (2014) - PMID: n.a.

Combination of Interleukin-12 gene Therapy, Metronomic Cyclophosphamide and DNA Cancer Vaccination Directs all Arms of the Immune System Towards Tumor EradicationDenies et al., Journal of Controlled Release (2014) - PMID:24887014

Decitabine Facilitates Immune Recognition of Sarcoma Cells by Upregulating CT Antigens, MHC molecules, and ICAM-1Krishnadas et al., Tumour Biol. (2014) - PMID: 24584817

T-Cell Responses after Haematopoietic Stem Cell Transplantation for Aggressive Relapsing-Remitting Multiple SclerosisBurman et al., Immunology (2013) - PMID: 23721329

Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1+ Acute Myeloid LeukemiaSundarasetty et al., Hum Gene Ther. (2013) - PMID: 23311414

Generation of Multi-Leukemia Antigen-Specific T Cells to Enhance the Graft-Versus-Leukemia Effect After Allogeneic Stem Cell TransplantWeber et al., Natur Leukemia (2013) - PMID: 23528871

Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemia—Implications for ImmunotherapyWeber et al., Clin. Cancer Res. (2013) - PMID: 23838315

Induction of Tumoricidal Function in CD4+ T Cells is Associated with Concomitant Memory and Terminally Differentiated PhenotypeHirschhorn-Cymerman et al., J. Exp. Med. (2012) - PMID: 23008334

Three Sensitive Assays Do Not Provide Evidence for Circulating HuD-specific T cells in The Blood of Patients with Paraneoplastic Neurological Syndromes with Anti-Hu Antibodiesde Jonste et al., Neuro Oncology. (2012) - PMID: 22591661

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma MetastasisWeide et al., J. Clin. Oncol. (2012) - PMID: 22529253

Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative LymphomaGerdemann et al., Molecular Therapy (2011) - PMID: 21915103

Improving T-Cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4Cruz et al., Clin. Cancer Res. (2011) - PMID: 21908573

Prophylactic Transfer of BCR-ABL–, PR1-, and WT1-Reactive Donor T Cells after T cell–Depleted Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Myeloid LeukemiaBornhäuser et al., Blood. (2011) - PMID: 21540460

Induction of Complete and Molecular Remissions in Acute Myeloid Leukemia by Wilms’ Tumor 1 Antigen-Targeted Dendritic Cell VaccinationTendeloo et al., PNAS (2010) - PMID: 20631300

Antigen-Specific Cytotoxic T Lymphocytes can Target Chemoresistant Side-Population Tumor Cells in Hodgkin’s LymphomaShafer et al., Leuk Lymphoma. (2010) - PMID: 20367572

High-Avidity Cytotoxic-T-lymphocytes Specific for a New Preferentially Expressed antigen of Melanoma (PRAME)-Derived Peptide can Target Leukemic- and Leukemic-precursor CellsQuintarelli et al., Blood (2010) - PMID: 21278353

MMP11: A Novel Target Antigen for Cancer ImmunotherapyPeruzzi et al., Clin Cancer Res (2009) - PMID: 19509157

Induction of Wilms' Tumor Protein (WT1)-Specific Antitumor Immunity Using a truncated WT1-Expressing Adenovirus VaccineOsada et al., Clin. Cancer Res. (2009) - PMID: 19351755

AtPTR1 and AtPTR5 Transport Sipeptides in PlantaKomarova et al., Plant Physiology Preview (2008) - PMID: 18753286

The Wilms' Tumor Antigen is a Novel Target for Human CD4 Regulatory T Cells: Implications for ImmunotherapyLehe et al., Cancer Res. (2008) - PMID: 18676860

Three-Dimensional MR Mapping of Angiogenesis with 5 1(3)-targeted Theranostic Nanoparticles in the MDA-MB-435 Xenograft Mouse ModelSchmieder et al., The FASEB Journal (2008) - PMID: 18697838

Complete Responses of Relapsed Lymphoma Following Genetic Modification of Tumor-Antigen Presenting Cells and T-lymphocyte TransferBollard et al., Blood (2007) - PMID: 17609424

An MVA Vaccine Overcomes Tolerance to Human p53 in Mice and HumansSong et al., Cancer Immunol Immunother (2007) - PMID: 17219151